文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

RESHAPE-HF2试验:二尖瓣经导管缘对缘修复的疗效与基线健康状况的关系

Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial.
PubMed 文献 · Eur Heart J · 2026-01-01

RESHAPE-HF2试验纳入505例心衰合并中重度室性继发性二尖瓣反流患者,评估二尖瓣经导管缘对缘修复(M-TEER)对临床结局的影响是否随基线健康状况(KCCQ-CSS)变化。

要点

  • 6个月时M-TEER组KCCQ-CSS改善≥5、≥10、≥15分的比例更高,恶化≥5分的比例更低。

核心结论

  • 在心衰合并中重度室性继发性二尖瓣反流患者中,M-TEER在不同KCCQ-CSS三分位组中均显示一致的心衰住院风险降低趋势,并随时间改善健康状况。

研究设计与样本

  • 采用Cox比例风险模型评估基线KCCQ-CSS对M-TEER临床结局效应的影响,并进行健康状况变化和应答者分析。

临床怎么用

  • 对于心衰合并中重度室性继发性二尖瓣反流患者,M-TEER的临床获益不因基线健康状况较差而减弱。
  • M-TEER可显著改善患者报告的健康状况,包括症状和总体 summary 评分,且持续至24个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Mitral transcatheter edge-to-edge repair (M-TEER) using the MitraClip device improves clinical outcomes in patients with moderate-to-severe ventricular secondary mitral regurgitation (vSMR) and heart failure (HF). This study evaluated whether the effects of M-TEER on clinical outcomes vary by baseline health status, as measured by the Kansas City Cardiomyopathy Questionnaire (KCCQ), and assessed the impact of M-TEER on health status post-randomization. METHODS: The RESHAPE-HF2 trial included patients with symptomatic HF and moderate-to-severe vSMR (mean effective regurgitant orifice area .25 cm2; 14% >.40 cm2, 23% <.20 cm2). The impact of baseline KCCQ-clinical summary score (CSS) on the effect of M-TEER on clinical outcomes was assessed using Cox proportional hazards models. Changes post-randomization in health status and responder analyses were performed to assess the odds ratio (OR) of improvement and deterioration in KCCQ scores. RESULTS: Among 505 patients, M-TEER reduced cardiovascular death or HF hospitalization risk [hazard ratio (HR): .71 (.48-1.05), .50 (.29-.85), and .73 (.38-1.41)] across KCCQ-CSS tertiles of <38.9, 38.9-66.1, and >66.1, respectively (P-trend = .53). Similar results were seen for total HF hospitalization (P-trend = .48). M-TEER improved KCCQ-CSS, total symptom score, and overall summary score at 1, 6, 12, and 24 months compared to medical therapy alone (P < .05 at all time points). More patients in the M-TEER arm experienced a ≥5-point [OR 3.38 (2.09-5.45)], ≥10-point [OR 3.12 (1.93-5.02)], and ≥15-point [OR 3.25 (1.94-5.45)] improvement, and less patients had a ≥5-point deterioration [OR .34 (.19-.57)] in KCCQ-CSS at 6 months. Similar results were seen across other KCCQ domains and all time points. CONCLUSIONS: In patients with HF and moderate-to-severe vSMR, M-TEER showed a consistent trend towards a lower risk of HF hospitalization, with or without cardiovascular death, across all KCCQ-CSS tertiles and improved health status over time.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Butler J, Khan MS, Friede T, et al. Mitral transcatheter edge-to-edge repair and outcomes according to baseline health status: the RESHAPE-HF2 trial. Eur Heart J. 2026. PMID: 41416702. doi:10.1093/eurheartj/ehaf1035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。